Wilex gets option to JNJ's Rencarex

Wilex (Munich, Germany) received an option from Centocor (Malvern, Penn.) to acquire exclusive U.S. marketing rights to Rencarex ( WX-G250) for renal cell carcinoma. Wilex previously licensed from Cen...